Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma.

Shao B, Bjaanæs MM, Helland Å, Schütte C, Conrad T.

PLoS One. 2019 Jan 31;14(1):e0204186. doi: 10.1371/journal.pone.0204186. eCollection 2019.

2.

EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.

Zhang R, Lai L, He J, Chen C, You D, Duan W, Dong X, Zhu Y, Lin L, Shen S, Guo Y, Su L, Shafer A, Moran S, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Wei Y, Chen F, Christiani DC.

Epigenetics. 2019 Jan 21:1-12. doi: 10.1080/15592294.2019.1573066. [Epub ahead of print]

PMID:
30665327
3.

DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients.

Guo Y, Zhang R, Shen S, Wei Y, Salama SM, Fleischer T, Bjaanæs MM, Karlsson A, Planck M, Su L, Zhu Z, Staaf J, Helland Å, Esteller M, Christiani DC.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1527-1535. doi: 10.1158/1055-9965.EPI-18-0454. Epub 2018 Sep 5.

PMID:
30185536
4.

A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer.

Shen S, Zhang R, Guo Y, Loehrer E, Wei Y, Zhu Y, Yuan Q, Moran S, Fleischer T, Bjaanaes MM, Karlsson A, Planck M, Staaf J, Helland Å, Esteller M, Su L, Chen F, Christiani DC.

Mol Oncol. 2018 Jun;12(6):913-924. doi: 10.1002/1878-0261.12204. Epub 2018 May 4.

5.

Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.

Wei Y, Liang J, Zhang R, Guo Y, Shen S, Su L, Lin X, Moran S, Helland Å, Bjaanæs MM, Karlsson A, Planck M, Esteller M, Fleischer T, Staaf J, Zhao Y, Chen F, Christiani DC.

Clin Epigenetics. 2018 Apr 2;10:41. doi: 10.1186/s13148-018-0474-3. eCollection 2018.

6.

A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer.

Halvorsen AR, Bjaanæs M, LeBlanc M, Holm AM, Bolstad N, Rubio L, Peñalver JC, Cervera J, Mojarrieta JC, López-Guerrero JA, Brustugun OT, Helland Å.

Oncotarget. 2016 Jun 14;7(24):37250-37259. doi: 10.18632/oncotarget.9363.

7.

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma--differences in histological subtypes.

Eide HA, Halvorsen AR, Bjaanæs MM, Piri H, Holm R, Solberg S, Jørgensen L, Brustugun OT, Kiserud CE, Helland Å.

BMC Cancer. 2016 Feb 8;16:71. doi: 10.1186/s12885-016-2104-9.

8.

Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis.

Bjaanæs MM, Fleischer T, Halvorsen AR, Daunay A, Busato F, Solberg S, Jørgensen L, Kure E, Edvardsen H, Børresen-Dale AL, Brustugun OT, Tost J, Kristensen V, Helland Å.

Mol Oncol. 2016 Feb;10(2):330-43. doi: 10.1016/j.molonc.2015.10.021. Epub 2015 Nov 6.

9.

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas.

Bjaanaes MM, Halvorsen AR, Solberg S, Jørgensen L, Dragani TA, Galvan A, Colombo F, Anderlini M, Pastorino U, Kure E, Børresen-Dale AL, Brustugun OT, Helland A.

Int J Cancer. 2014 Oct 15;135(8):1812-21. doi: 10.1002/ijc.28828. Epub 2014 Mar 14.

Supplemental Content

Loading ...
Support Center